Reduction in Lymphocytes |
Lymphocyte Recovery |
||
|
MAVENCLAD has been shown to exert long-lasting effects by preferentially targeting lymphocytes and the autoimmune processes involved in MS |
- Median lymphocyte counts: returned to the normal range at week 84, approximately 30 weeks (7 months) after the last dose - 75% of lymphocyte counts: returned to the normal range by week 144, approximately 90 weeks (21 months) after the last dose |
Footnotes and references
Reference
- MAVENCLAD™ Product Monograph. EMD Serono. November 2017.